메뉴 건너뛰기




Volumn 41, Issue 4, 2009, Pages 242-256

Clinical review: Impact of statin substitution policies on patient outcomes

Author keywords

Cardiovascular disease; Cholesterol; Cost effectiveness; Low density lipoprotein; Policy; Statin; Substitution; Switching

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; GENERIC DRUG;

EID: 67649388476     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.1080/07853890902729786     Document Type: Review
Times cited : (23)

References (72)
  • 1
    • 62949168411 scopus 로고    scopus 로고
    • European cardiovascular disease statistics Last update 14 Feb 2008 accessed 29 Feb 2008
    • European cardiovascular disease statistics 2008. European Heart Network. Last update 14 Feb 2008. Available at: http:// www.ehnheart.org/files/ statistics%202008%20web-161229A. pdf (accessed 29 Feb 2008).
    • (2008) European Heart Network
  • 2
    • 35148892823 scopus 로고    scopus 로고
    • European guidelines on cardiovascular disease prevention in clinical practice: Executive summary
    • Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J. 2007;28:2375-2414
    • (2007) Eur Heart J , vol.28 , pp. 2375-2414
    • Graham, I.1    Atar, D.2    Borch-Johnsen, K.3    Boysen, G.4    Burell, G.5    Cifkova, R.6
  • 3
    • 70350476998 scopus 로고
    • Clinical reality of coronary prevention in Europe: A comparison of EUROASPIRE I, II and III surveys. Time trends in cardiovascular disease prevention in clinical practice September
    • March 2007 press releases. Last update 2 Sep 2007 accessed 10 Oct 2007
    • Wood D. Clinical reality of coronary prevention in Europe: A comparison of EUROASPIRE I, II and III surveys. Time trends in cardiovascular disease prevention in clinical practice September 1994-March 2007. ESC Congress 2007 press releases. Last update 2 Sep 2007. Available at: http:// www.escardio.org/vpo/press + area/2007-esc-congress-pr/wo od-euroaspire.htm (accessed 10 Oct 2007).
    • (1994) ESC Congress 2007
    • Wood, D.1
  • 4
    • 37149057185 scopus 로고    scopus 로고
    • Achievement of guideline-defined treatment goals in primary care: The German Coronary Risk Management (CoRiMa) study
    • Geller JC, Cassens S, Brosz M, Keil U, Bernarding J, Kropf S, et al. Achievement of guideline-defined treatment goals in primary care: the German Coronary Risk Management (CoRiMa) study. Eur Heart J. 2007;28:3051-3058
    • (2007) Eur Heart J , vol.28 , pp. 3051-3058
    • Geller, J.C.1    Cassens, S.2    Brosz, M.3    Keil, U.4    Bernarding, J.5    Kropf, S.6
  • 5
    • 26244432388 scopus 로고    scopus 로고
    • Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    • Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-1278
    • (2005) Lancet , vol.366 , pp. 1267-1278
    • Baigent, C.1    Keech, A.2    Kearney, P.M.3    Blackwell, L.4    Buck, G.5    Pollicino, C.6
  • 6
    • 42649102640 scopus 로고    scopus 로고
    • An update on regional variation in cardiovascular mortality within Europe
    • Muller-Nordhorn J, Binting S, Roll S, Willich SN. An update on regional variation in cardiovascular mortality within Europe. Eur Heart J. 2008;29:1316-1326
    • (2008) Eur Heart J , vol.29 , pp. 1316-1326
    • Muller-Nordhorn, J.1    Binting, S.2    Roll, S.3    Willich, S.N.4
  • 7
    • 33644932647 scopus 로고    scopus 로고
    • Levels of dyslipidaemia and improvement in its management in England: Results from the Health Survey for England
    • Primatesta P, Poulter NR. Levels of dyslipidaemia and improvement in its management in England: results from the Health Survey for England 2003. Clin Endocrinol (Oxf). 2006;64:292-298
    • (2003) Clin Endocrinol (Oxf). , vol.2006 , Issue.64 , pp. 292-298
    • Primatesta, P.1    Poulter, N.R.2
  • 8
    • 34147165075 scopus 로고    scopus 로고
    • Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: Data from National Health and Nutrition Examination Survey 1999 to 2002
    • Keevil JG, Cullen MW, Gangnon R, McBride PE, Stein JH. Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999 to 2002. Circulation. 2007;115:1363-1370
    • Circulation , vol.2007 , Issue.115 , pp. 1363-1370
    • Keevil, J.G.1    Cullen, M.W.2    Gangnon, R.3    McBride, P.E.4    Stein, J.H.5
  • 10
    • 9444245001 scopus 로고    scopus 로고
    • Intensive integrated therapy of type 2 diabetes: Implications for long-term prognosis
    • Gaede P, Pedersen O. Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis. Diabetes. 2004;53 Suppl 3:S39-7.
    • (2004) Diabetes , vol.53 , Issue.SUPPL. 3
    • Gaede, P.1    Pedersen, O.2
  • 12
    • 0037102131 scopus 로고    scopus 로고
    • Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE)
    • Steg PG, Goldberg RJ, Gore JM, Fox KA, Eagle KA, Flather MD, et al. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE). Am J Cardiol. 2002;90:358-363
    • (2002) Am J Cardiol , vol.90 , pp. 358-363
    • Steg, P.G.1    Goldberg, R.J.2    Gore, J.M.3    Fox, K.A.4    Eagle, K.A.5    Flather, M.D.6
  • 13
    • 0842346319 scopus 로고    scopus 로고
    • Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events (GRACE))
    • Goldberg RJ, Currie K, White K, Brieger D, Steg PG, Goodman SG, et al. Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (the Global Registry of Acute Coronary Events (GRACE)). Am J Cardiol. 2004;93:288-293
    • (2004) Am J Cardiol , vol.93 , pp. 288-293
    • Goldberg, R.J.1    Currie, K.2    White, K.3    Brieger, D.4    Steg, P.G.5    Goodman, S.G.6
  • 14
    • 0037524291 scopus 로고    scopus 로고
    • Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events
    • Foley KA, Simpson RJ Jr, Crouse JR 3rd, Weiss TW, Markson LE, Alexander CM. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol. 2003;92:79-81.
    • (2003) Am J Cardiol , vol.92 , pp. 79-81
    • Foley, K.A.1    Simpson Jr., R.J.2    Crouse III, J.R.3    Weiss, T.W.4    Markson, L.E.5    Alexander, C.M.6
  • 15
    • 33646750506 scopus 로고    scopus 로고
    • Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction
    • Gislason GH, Rasmussen JN, Abildstrom SZ, Gadsboll N, Buch P, Friberg J, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J. 2006;27:1153-1158
    • (2006) Eur Heart J , vol.27 , pp. 1153-1158
    • Gislason, G.H.1    Rasmussen, J.N.2    Abildstrom, S.Z.3    Gadsboll, N.4    Buch, P.5    Friberg, J.6
  • 16
    • 41449103034 scopus 로고    scopus 로고
    • A critical gap between recommended and achieved LDL-cholesterol levels. Results of statin therapy in Slovakia
    • Gajdos M, Krivosikova Z, Uhliar R. A critical gap between recommended and achieved LDL-cholesterol levels. Results of statin therapy in Slovakia. Bratisl Lek Listy. 2007;108:388-392
    • (2007) Bratisl Lek Listy , vol.108 , pp. 388-392
    • Gajdos, M.1    Krivosikova, Z.2    Uhliar, R.3
  • 17
    • 18344368202 scopus 로고    scopus 로고
    • Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates
    • Baessler A, Fischer M, Huf V, Mell S, Hengstenberg C, Mayer B, et al. Failure to achieve recommended LDL cholesterol levels by suboptimal statin therapy relates to elevated cardiac event rates. Int J Cardiol. 2005;101:293-298
    • (2005) Int J Cardiol , vol.101 , pp. 293-298
    • Baessler, A.1    Fischer, M.2    Huf, V.3    Mell, S.4    Hengstenberg, C.5    Mayer, B.6
  • 18
    • 34547772153 scopus 로고    scopus 로고
    • Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes
    • Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28:1598-1660
    • (2007) Eur Heart J , vol.28 , pp. 1598-1660
    • Bassand, J.P.1    Hamm, C.W.2    Ardissino, D.3    Boersma, E.4    Budaj, A.5    Fernandez-Aviles, F.6
  • 19
    • 33846414720 scopus 로고    scopus 로고
    • Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)
    • Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28:88-136.
    • (2007) Eur Heart J , vol.28 , pp. 88-136
    • Ryden, L.1    Standl, E.2    Bartnik, M.3    Van Den Berghe, G.4    Betteridge, J.5    De Boer, M.J.6
  • 21
    • 0042512336 scopus 로고    scopus 로고
    • European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice
    • De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J. 2003;24:1601-1610
    • (2003) Eur Heart J , vol.24 , pp. 1601-1610
    • De Backer, G.1    Ambrosioni, E.2    Borch-Johnsen, K.3    Brotons, C.4    Cifkova, R.5    Dallongeville, J.6    Al, E.7
  • 22
    • 38049033935 scopus 로고    scopus 로고
    • Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis
    • Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371:117-125
    • (2008) Lancet , vol.371 , pp. 117-125
    • Kearney, P.M.1    Blackwell, L.2    Collins, R.3    Keech, A.4    Simes, J.5    Peto, R.6
  • 23
    • 15944410609 scopus 로고    scopus 로고
    • Intensive lipid lowering with atorvastatin in patients with stable coronary disease
    • LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435
    • (2005) N Engl J Med , vol.352 , pp. 1425-1435
    • Larosa, J.C.1    Grundy, S.M.2    Waters, D.D.3    Shear, C.4    Barter, P.5    Fruchart, J.C.6
  • 24
    • 34547970751 scopus 로고    scopus 로고
    • Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets (TNT) study)
    • LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H. Safety and efficacy of atorvastatin-induced very low-density lipoprotein cholesterol levels in patients with coronary heart disease (a post hoc analysis of the Treating to New Targets (TNT) study). Am J Cardiol. 2007;100:747-752
    • (2007) Am J Cardiol , vol.100 , pp. 747-752
    • Larosa, J.C.1    Grundy, S.M.2    Kastelein, J.J.3    Kostis, J.B.4    Greten, H.5
  • 25
    • 27744603499 scopus 로고    scopus 로고
    • High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial
    • Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437-2445
    • (2005) JAMA , vol.294 , pp. 2437-2445
    • Pedersen, T.R.1    Faergeman, O.2    Kastelein, J.J.3    Olsson, A.G.4    Tikkanen, M.J.5    Holme, I.6
  • 26
    • 11144355354 scopus 로고    scopus 로고
    • Intensive versus moderate lipid lowering with statins after acute coronary syndromes
    • Cannon C, Braunwald E, McCabe C, Rader D, Rouleau J, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504
    • (2004) N Engl J Med , vol.350 , pp. 1495-1504
    • Cannon, C.1    Braunwald, E.2    McCabe, C.3    Rader, D.4    Rouleau, J.5    Belder, R.6
  • 27
    • 4544243333 scopus 로고    scopus 로고
    • Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial
    • de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292:1307-1316
    • (2004) JAMA , vol.292 , pp. 1307-1316
    • De Lemos, J.A.1    Blazing, M.A.2    Wiviott, S.D.3    Lewis, E.F.4    Fox, K.A.5    White, H.D.6
  • 29
    • 34247479529 scopus 로고    scopus 로고
    • Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy
    • Silva M, Matthews ML, Jarvis C, Nolan NM, Belliveau P, Malloy M, et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007;29:253-260
    • (2007) Clin Ther , vol.29 , pp. 253-260
    • Silva, M.1    Matthews, M.L.2    Jarvis, C.3    Nolan, N.M.4    Belliveau, P.5    Malloy, M.6
  • 30
    • 0037420492 scopus 로고    scopus 로고
    • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial
    • DOI 10.1016/S0140-6736(03)12948-0
    • Sever P, Dahlof B, PoulterN, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial*Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158 (Pubitemid 36398384)
    • (2003) Lancet , vol.361 , Issue.9364 , pp. 1149-1158
    • Sever, P.S.1    Dahlof, B.2    Poulter, N.R.3    Wedel, H.4    Beevers, G.5    Caulfield, M.6    Collins, R.7    Kjeldsen, S.E.8    Kristinsson, A.9    McInnes, G.T.10    Mehlsen, J.11    Nieminen, M.12    O'Brien, E.13    Ostergren, J.14
  • 31
    • 56749106312 scopus 로고    scopus 로고
    • Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
    • Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207
    • (2008) N Engl J Med , vol.359 , pp. 2195-2207
    • Ridker, P.M.1    Danielson, E.2    Fonseca, F.A.3    Genest, J.4    Jr G.Am5    Kastelein, J.J.6
  • 32
    • 7044222840 scopus 로고    scopus 로고
    • Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: The alliance study
    • Koren MJ, Hunninghake DB. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol. 2004;44:1772-1779
    • (2004) J Am Coll Cardiol , vol.44 , pp. 1772-1779
    • Koren, M.J.1    Hunninghake, D.B.2
  • 34
    • 45149123632 scopus 로고    scopus 로고
    • Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin: A large database analysis of managed care plans in the US
    • Foody J, Joyce A, Rudolph A, Liu LZ, Benner J. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin: a large database analysis of managed care plans in the US. Clin Ther. 2008;30:195-205.
    • (2008) Clin Ther , vol.30 , pp. 195-205
    • Foody, J.1    Joyce, A.2    Rudolph, A.3    Liu, L.Z.4    Benner, J.5
  • 35
    • 16844382829 scopus 로고    scopus 로고
    • Pathological changes in acute coronary syndromes: The role of statin therapy in the modulation of inflammation, endothelial function and coagulation
    • Ray KK, Cannon CP. Pathological changes in acute coronary syndromes: the role of statin therapy in the modulation of inflammation, endothelial function and coagulation. J Thromb Thrombolysis. 2004;18:89-101.
    • (2004) J Thromb Thrombolysis , vol.18 , pp. 89-101
    • Ray, K.K.1    Cannon, C.P.2
  • 36
    • 33749002873 scopus 로고    scopus 로고
    • The effect of early, intensive statin therapy on acute coronary syndrome: A meta-analysis of randomized controlled trials
    • Hulten E, Jackson JL, Douglas K, George S, Villines TC. The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:1814-1821
    • (2006) Arch Intern Med , vol.166 , pp. 1814-1821
    • Hulten, E.1    Jackson, J.L.2    Douglas, K.3    George, S.4    Villines, T.C.5
  • 37
    • 0035804846 scopus 로고    scopus 로고
    • Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial
    • Schwartz G, Olsson A, Ezekowitz M, Ganz P, Oliver M, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711-1718
    • (2001) JAMA , vol.285 , pp. 1711-1718
    • Schwartz, G.1    Olsson, A.2    Ezekowitz, M.3    Ganz, P.4    Oliver, M.5    Waters, D.6
  • 38
    • 17944396864 scopus 로고    scopus 로고
    • Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: The Pravastatin in Acute Coronary Treatment (PACT) trial
    • Thompson PL, Meredith I, Amerena J, Campbell TJ, Sloman JG, Harris PJ. Effect of pravastatin compared with placebo initiated within 24 hours of onset of acute myocardial infarction or unstable angina: the Pravastatin in Acute Coronary Treatment (PACT) trial. Am Heart J. 2004;148:e2.
    • (2004) Am Heart J , vol.148
    • Thompson, P.L.1    Meredith, I.2    Amerena, J.3    Campbell, T.J.4    Sloman, J.G.5    Harris, P.J.6
  • 39
    • 70749159902 scopus 로고    scopus 로고
    • The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome
    • Aug Epub ahead of print
    • Yun KH, Jeong MH, Oh SK, Rhee SJ, Park EM, Lee EM, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol. 2008 Aug 13 (Epub ahead of print).
    • (2008) Int J Cardiol , vol.13
    • Yun, K.H.1    Jeong, M.H.2    Oh, S.K.3    Rhee, S.J.4    Park, E.M.5    Lee, E.M.6
  • 40
    • 0035820313 scopus 로고    scopus 로고
    • Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study
    • Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001;357:1063-1068
    • (2001) Lancet , vol.357 , pp. 1063-1068
    • Aronow, H.D.1    Topol, E.J.2    Roe, M.T.3    Houghtaling, P.L.4    Wolski, K.E.5    Lincoff, A.M.6
  • 41
    • 17844406130 scopus 로고    scopus 로고
    • Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: Observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial
    • Smith CS, Cannon CP, McCabe CH, Murphy SA, Bentley J, Braunwald E. Early initiation of lipid-lowering therapy for acute coronary syndromes improves compliance with guideline recommendations: observations from the Orbofiban in Patients with Unstable Coronary Syndromes (OPUS-TIMI 16) trial. Am Heart J. 2005;149:444-450
    • (2005) Am Heart J , vol.149 , pp. 444-450
    • Smith, C.S.1    Cannon, C.P.2    McCabe, C.H.3    Murphy, S.A.4    Bentley, J.5    Braunwald, E.6
  • 42
    • 0001276528 scopus 로고    scopus 로고
    • Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: Observations from OPUS-TIMI 16 [Abstract]
    • Cannon C, McCabe C, Bentley J, Braunwald E. Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: Observations from OPUS-TIMI 16 [Abstract]. J Am Coll Cardiol. 2001;37 Suppl:A334.
    • (2001) J Am Coll Cardiol , vol.37 , Issue.SUPPL.
    • Cannon, C.1    McCabe, C.2    Bentley, J.3    Braunwald, E.4
  • 43
    • 0035941512 scopus 로고    scopus 로고
    • Early statin treatment following acute myocardial infarction and 1-year survival
    • Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA. 2001;285:430-436
    • (2001) JAMA , vol.285 , pp. 430-436
    • Stenestrand, U.1    Wallentin, L.2
  • 45
    • 23944497531 scopus 로고    scopus 로고
    • Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality
    • Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, et al. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol. 2005;96:611-616
    • (2005) Am J Cardiol , vol.96 , pp. 611-616
    • Spencer, F.A.1    Goldberg, R.J.2    Gore, J.M.3    Fox, K.A.4    Avezum, A.5    Agnelli, G.6    Al, E.7
  • 46
    • 29244483080 scopus 로고    scopus 로고
    • Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients
    • Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol. 2006;97:61-67
    • (2006) Am J Cardiol , vol.97 , pp. 61-67
    • Newman, C.1    Tsai, J.2    Szarek, M.3    Luo, D.4    Gibson, E.5
  • 47
    • 44049091020 scopus 로고    scopus 로고
    • Clinical efficacy and safety of statins in managing cardiovascular risk
    • Kapur NK, Musunuru K. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2008;4:341-353
    • (2008) Vasc Health Risk Manag , vol.4 , pp. 341-353
    • Kapur, N.K.1    Musunuru, K.2
  • 50
    • 34447627450 scopus 로고    scopus 로고
    • Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: Insights from large randomized statin trials
    • Alsheikh-Ali AA, Maddukuri PV, Han H, Karas RH. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol. 2007;50:409-418
    • (2007) J Am Coll Cardiol , vol.50 , pp. 409-418
    • Alsheikh-Ali, A.A.1    Maddukuri, P.V.2    Han, H.3    Karas, R.H.4
  • 51
    • 33846111227 scopus 로고    scopus 로고
    • Statins and the risk of lung, breast, and colorectal cancer in the elderly
    • Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation. 2007;115:27-33.
    • (2007) Circulation , vol.115 , pp. 27-33
    • Setoguchi, S.1    Glynn, R.J.2    Avorn, J.3    Mogun, H.4    Schneeweiss, S.5
  • 52
    • 34248196018 scopus 로고    scopus 로고
    • Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease
    • Chan PS, Nallamothu BK, Gurm HS, Hayward RA, Vijan S. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease. Circulation. 2007;115:2398-2409
    • (2007) Circulation , vol.115 , pp. 2398-2409
    • Chan, P.S.1    Nallamothu, B.K.2    Gurm, H.S.3    Hayward, R.A.4    Vijan, S.5
  • 53
    • 28044454022 scopus 로고    scopus 로고
    • Cost-effectiveness of intensive therapy in patients with acute coronary syndrome [Abstract]
    • Koren M, Schwartz S, Drummond M. Cost-effectiveness of intensive therapy in patients with acute coronary syndrome [Abstract]. J Am Coll Cardiol. 2005;45:347A.
    • (2005) J Am Coll Cardiol , vol.45
    • Koren, M.1    Schwartz, S.2    Drummond, M.3
  • 54
    • 70350476997 scopus 로고    scopus 로고
    • Cost-effectiveness of intensive lipid-lowering treatment in secondary cardiovascular prevention in Spain and Germany [Abstract]
    • Taylor D, Pandya A, Thompson D, Chu P, Graff J, LaRosa J, et al. Cost-effectiveness of intensive lipid-lowering treatment in secondary cardiovascular prevention in Spain and Germany [Abstract]. Atheroscler Suppl. 2007;8:125.
    • (2007) Atheroscler Suppl , vol.8 , pp. 125
    • Taylor, D.1    Pandya, A.2    Thompson, D.3    Chu, P.4    Graff, J.5    Larosa, J.6
  • 55
    • 34548316230 scopus 로고    scopus 로고
    • Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin
    • Lindgren P, Graff J, Olsson AG, Pedersen TJ, Jonsson B. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. Eur Heart J. 2007;28:1448-1453
    • (2007) Eur Heart J , vol.28 , pp. 1448-1453
    • Lindgren, P.1    Graff, J.2    Olsson, A.G.3    Pedersen, T.J.4    Jonsson, B.5
  • 56
    • 34547210808 scopus 로고    scopus 로고
    • Economic impacts attributable to the early clinical benefit of atorvastatin therapy*a US managed care perspective
    • Straka RJ, Mamdani M, Damen J, Kuntze CE, Liu LZ, Botteman MF, et al. Economic impacts attributable to the early clinical benefit of atorvastatin therapy*a US managed care perspective. Curr Med Res Opin. 2007;23:1517-1529
    • (2007) Curr Med Res Opin , vol.23 , pp. 1517-1529
    • Straka, R.J.1    Mamdani, M.2    Damen, J.3    Kuntze, C.E.4    Liu, L.Z.5    Botteman, M.F.6
  • 57
    • 38049084305 scopus 로고    scopus 로고
    • Cost-effectiveness analysis of atorvastatin compared to simvastatin treatment in Greece
    • Yfantopoulos J, Papagiannopoulou V. Cost-effectiveness analysis of atorvastatin compared to simvastatin treatment in Greece. Arch Hel Med. 2007;24:463-470
    • (2007) Arch Hel Med , vol.24 , pp. 463-470
    • Yfantopoulos, J.1    Papagiannopoulou, V.2
  • 58
    • 53749086313 scopus 로고    scopus 로고
    • Statin cost-effectiveness comparisons using real-world effectiveness data: Formulary implications
    • Ohsfeldt RL, Gandhi SK, Fox KM, McKenney JM. Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications. Value Health. 2008;11:1061-1069
    • (2008) Value Health , vol.11 , pp. 1061-1069
    • Ohsfeldt, R.L.1    Gandhi, S.K.2    Fox, K.M.3    McKenney, J.M.4
  • 59
    • 41949105051 scopus 로고    scopus 로고
    • Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: Rosuvastatin compared with other statins in usual care
    • Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care. Expert Opin Pharmacother. 2008;9:669-676
    • (2008) Expert Opin Pharmacother , vol.9 , pp. 669-676
    • Harley, C.R.1    Gandhi, S.K.2    Heien, H.3    McDonough, K.4    Nelson, S.P.5
  • 60
  • 61
    • 27744549370 scopus 로고    scopus 로고
    • The effect of switching on compliance and persistence: The case of statin treatment
    • Thiebaud P, Patel BV, Nichol MB, Berenbeim DM. The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care. 2005;11:670.
    • (2005) Am J Manag Care , vol.11 , pp. 670
    • Thiebaud, P.1    Patel, B.V.2    Nichol, M.B.3    Berenbeim, D.M.4
  • 62
    • 34547822507 scopus 로고    scopus 로고
    • Therapeutic dose assessment of patient switching from atorvastatin to simvastatin
    • Hess G, Sanders KN, Hill J, Liu LZ. Therapeutic dose assessment of patient switching from atorvastatin to simvastatin. Am J Manag Care. 2007;13 Suppl 3:S80-5.
    • (2007) Am J Manag Care , vol.13 , Issue.SUPPL. 3
    • Hess, G.1    Sanders, K.N.2    Hill, J.3    Liu, L.Z.4
  • 63
    • 37849044165 scopus 로고    scopus 로고
    • Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting
    • Fox KM, Gandhi SK, Ohsfeldt RL, Davidson MH. Comparison of low-density lipoprotein cholesterol reduction after switching patients on other statins to rosuvastatin or simvastatin in a real-world clinical practice setting. Am J Manag Care. 2007;13 Suppl 10:S270-5.
    • (2007) Am J Manag Care , vol.13 , Issue.SUPPL. 10
    • Fox, K.M.1    Gandhi, S.K.2    Ohsfeldt, R.L.3    Davidson, M.H.4
  • 65
    • 0032488379 scopus 로고    scopus 로고
    • Increased thrombotic vascular events after change of statin
    • Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet. 1998;352:1830-1831
    • (1998) Lancet , vol.352 , pp. 1830-1831
    • Thomas, M.1    Mann, J.2
  • 66
    • 33845892767 scopus 로고    scopus 로고
    • Cholesterol lowering in patients with CHD and metabolic syndrome [Letter]
    • Butler R, Wainwright J. Cholesterol lowering in patients with CHD and metabolic syndrome [Letter]. Lancet. 2007;369:27.
    • (2007) Lancet , vol.369 , pp. 27
    • Butler, R.1    Wainwright, J.2
  • 69
    • 43949093826 scopus 로고    scopus 로고
    • Can cheap generic statins achieve national cholesterol lowering targets?
    • Petty D, Lloyd D. Can cheap generic statins achieve national cholesterol lowering targets? J Health Serv Res Policy. 2008;13:99-102.
    • (2008) J Health Serv Res Policy , vol.13 , pp. 99-102
    • Petty, D.1    Lloyd, D.2
  • 70
    • 38849113845 scopus 로고    scopus 로고
    • Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on
    • Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract. 2008;62:480.
    • (2008) Int J Clin Pract , vol.62 , pp. 480
    • Usher-Smith, J.1    Ramsbottom, T.2    Pearmain, H.3    Kirby, M.4
  • 71
    • 33847028362 scopus 로고    scopus 로고
    • Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting
    • Usher-Smith JA, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting. Int J Clin Pract. 2007;61:15-23.
    • (2007) Int J Clin Pract , vol.61 , pp. 15-23
    • Usher-Smith, J.A.1    Ramsbottom, T.2    Pearmain, H.3    Kirby, M.4
  • 72
    • 42949138132 scopus 로고    scopus 로고
    • Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients
    • Miller AE, Hansen LB, Saseen JJ. Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients. Pharmacotherapy. 2008;28:553-561
    • (2008) Pharmacotherapy , vol.28 , pp. 553-561
    • Miller, A.E.1    Hansen, L.B.2    Saseen, J.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.